An Australia-specific guide to separating ARTG-listed or registered therapeutic goods, practitioner and pharmacy services, personal imports, and research-only listings before comparing cost.
Australian search results can combine therapeutic goods on the ARTG, practitioner or pharmacy services, conditional personal-import routes, and laboratory suppliers. Those categories answer different regulatory questions and should not share one price ranking.
Use this checklist to verify the local product, seller, and supply records before comparing price or availability.
Check the product, sponsor, ingredient, and ARTG identifier in the TGA database; goods not included generally cannot be supplied unless an exemption or access pathway applies.
Use Ahpra’s public register to match the person, profession, current registration status, and state instead of relying on a clinic biography.
Personal importation has quantity and eligibility conditions, and the TGA states imported products have not been evaluated for safety, quality, or efficacy.
Each answer is tied to the local records below so you can see what is confirmed, what remains unknown, and where to recheck it. Open the primary sources ↓
No blanket answer is supportable. Check the product, sponsor, ingredient, and ARTG identifier in the TGA database; goods not included generally cannot be supplied unless an exemption or access pathway applies. In Australia, begin with Searching the Australian Register of Therapeutic Goods from Therapeutic Goods Administration; the product, seller, and supply route still need to resolve to the same current record.
No. Peptide Local withholds a commercial table for Australia until seller category, local delivery, regulatory or research status, exact price, and observation date are all sourced. This page is a verification route, not a shopping recommendation.
For Australia, start with Searching the Australian Register of Therapeutic Goods from Therapeutic Goods Administration, then open Personal Importation Scheme from Therapeutic Goods Administration. The records answer separate questions, so confirm each current entry instead of treating one match as proof of the seller, product, and route together.
Resolve the identity first, then use this country’s official product and seller records. A matching name never transfers approval, trial evidence, or seller authority.
KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.
Primary identity sourceFDA briefing document for KPV-related bulk drug substancesU.S. Food and Drug Administration ↗BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗The TGA states that Melanotan II is prescription-only in Australia, is not approved for sale or use as a tanning agent, and has no products on the Australian Register of Therapeutic Goods. A same-name listing still requires an exact product, prescription, import, seller, and supply assessment.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceCheck the FDA Purple Book product recordU.S. Food and Drug Administration ↗AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the current DailyMed drug labelNational Library of Medicine, DailyMed ↗CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Retatrutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceTRIUMPH-1 Phase 3 study - NCT05929066ClinicalTrials.gov ↗Mazdutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceGLORY-1 Phase 3 study - NCT05607680ClinicalTrials.gov ↗Ecnoglutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSLIMMER Phase 3 study - NCT05813795ClinicalTrials.gov ↗Enicepatide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceCT388-103 Phase 2 study - NCT06525935ClinicalTrials.gov ↗Eloralintide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceEloralintide Phase 2 study - NCT06230523ClinicalTrials.gov ↗Cagrilintide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗Petrelintide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceZUPREME-1 Phase 2 study - NCT06662539ClinicalTrials.gov ↗CagriSema is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗MariTide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourcePhase 2 dose-ranging study - NCT05669599ClinicalTrials.gov ↗Survodutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSYNCHRONIZE-1 Phase 3 study - NCT06066515ClinicalTrials.gov ↗VK2735 is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceVENTURE injectable Phase 2 study - NCT06068946ClinicalTrials.gov ↗Pemvidutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceIMPACT Phase 2b MASH study - NCT05989711ClinicalTrials.gov ↗Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceAMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414ClinicalTrials.gov ↗Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.
Primary identity sourceCurrent ZEPBOUND prescribing informationNational Library of Medicine, DailyMed ↗Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.
Primary identity sourceCurrent FOUNDAYO prescribing informationNational Library of Medicine, DailyMed ↗Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.
Primary identity sourceCurrent WEGOVY prescribing informationNational Library of Medicine, DailyMed ↗DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem substance recordNational Library of Medicine, PubChem ↗Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the current SCENESSE labelNational Library of Medicine, DailyMed ↗NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA orphan-drug recordU.S. Food and Drug Administration ↗Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.
Primary identity sourceCurrent EGRIFTA WR prescribing informationNational Library of Medicine, DailyMed ↗Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.
Primary identity sourceCurrent SAXENDA prescribing informationNational Library of Medicine, DailyMed ↗SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.
Primary identity sourceCurrent SCENESSE prescribing informationNational Library of Medicine, DailyMed ↗VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.
Primary identity sourceCurrent VYLEESI prescribing informationNational Library of Medicine, DailyMed ↗Peptide Local will not manufacture a ranking from thin data. A local table appears only after seller category, authorization or research status, delivery market, price, and source date can all be stated clearly.
Official sources are linked directly. Open them to confirm the current record; this page is a guide, not a substitute for the regulator.